血浆蛋白治疗市场：依产品、应用分类 - 2025-2030 年全球预测

血浆蛋白治疗市场2023年估值为325.5亿美元，预计到2024年将达到361.9亿美元，复合年增长率为11.37%，预计到2030年将达到691.8亿美元。

血浆蛋白疗法包括源自人类血浆蛋白的治疗方法，用于治疗血友病、免疫力缺乏和罕见疾病等疾病。其中包括旨在满足关键患者需求的治疗药物，例如免疫球蛋白、白蛋白和凝血因子。需求在于这些蛋白质提供的独特治疗益处，通常使它们对于没有其他选择的患者至关重要。其应用范围广泛，从凝血病和免疫力缺乏的治疗和管理到急诊医学的重症加护。最终用途主要是医院、专科诊所和研究机构，这些地方迫切需要有效的治疗方法。该市场是由罕见疾病的增加、血浆分馏技术的进步以及医疗保健支出的增加等因素所推动的。免疫球蛋白需求的快速成长和重组疗法的技术进步，以及新兴地区因医疗基础设施改善而带来的市场扩张，推动了最新的商机。为了利用这些机会，公司应专注于策略伙伴关係和区域扩张。然而，市场成长目前受到治疗成本上涨、严格的法律规范以及血浆捐赠道德问题等限制因素的挑战。此外，产品製造的复杂性和有限的血浆供应也构成了主要障碍。最佳创新领域包括开发新的血浆治疗方法、提高血浆采集效率以及探索基因工程以改善基因工程替代品。该市场的主要特征是竞争激烈，策略合併、收购和联盟在推动成长方面很常见。公司应优先投资新型疗法和潜在合成替代品的研究，以扩大供应。总体而言，由于技术创新和准入范围扩大，市场可望成长，但必须克服成本、监管和供应链复杂性的挑战。

市场动态：快速发展的血浆蛋白治疗市场的关键市场洞察

血浆蛋白治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

• 市场驱动因素
  • 自体免疫疾病和神经系统疾病的盛行率增加
  • 患者一生需要定期输液或註射
  • 血浆蛋白治疗的患者可近性和可负担性迅速增加
• 市场限制因素
  • 血浆蛋白疗法的副作用
• 市场机会
  • 血浆蛋白相关研究开发活动的活性化
  • 开发高效血浆蛋白萃取/製造工艺
• 市场挑战
  • 关于血浆蛋白处理的严格规定

波特五力：驾驭血浆蛋白治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解血浆蛋白治疗市场的外部影响

外部宏观环境因素在塑造血浆蛋白治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解血浆蛋白治疗市场的竞争格局

血浆蛋白治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵血浆蛋白治疗市场供应商的绩效评估

FPNV定位矩阵是评估血浆蛋白治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

• 市场动态
  • 促进因素
    • 自体免疫疾病和神经系统疾病的盛行率增加
    • 患者一生需要定期输液和注射
    • 迅速提高患者血浆蛋白治疗的可近性和可负担性
  • 抑制因素
    • 血浆蛋白治疗的不良反应
  • 机会
    • 血浆蛋白相关的研发活动增加
    • 开发高效的蛋白质血浆萃取和製造工艺
  • 任务
    • 关于血浆蛋白处理的严格规定
• 市场区隔分析
  • 产品：增加使用 C1 酯酶抑制剂来控制和预防与 HAE 相关的肿胀发作
  • 应用：扩大血浆蛋白疗法在癌症和自体免疫疾病扩散导致的继发性免疫力缺乏中的应用
• 波特五力分析
• PESTEL分析
  • 政治的
  • 经济
  • 社群
  • 技术的
  • 合法地
  • 环境
• 客户客製化

第六章血浆蛋白治疗市场：副产品

• 白蛋白
• C1酯酶抑制剂
• 凝血因子
• 超免疫球蛋白
• 免疫球蛋白

第七章血浆蛋白治疗市场：依应用分类

• 遗传性血管性水肿
• 特发性血小板减少紫斑症
• 原发性免疫力缺乏
• 继发性免疫力缺乏缺陷

第八章美洲血浆蛋白治疗市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第九章亚太血浆蛋白治疗市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第十章欧洲/中东/非洲血浆蛋白治疗市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第十一章竞争格局

• 2023 年市场占有率分析
• FPNV 定位矩阵，2023
• 竞争情境分析
  • GC Biopharma 在印尼举行血浆分馏工厂奠基仪式
  • Plasmagen Biosciences 在班加罗尔 Kolar 开设了最先进的新血浆产品製造工厂
  • 武田将耗资 7.7 亿美元在日本兴建血浆分馏治疗工厂

公司名单

• Bio Products Laboratory Ltd.
• CSL Limited
• Takeda Pharmaceutical Company Limited
• DiaPharma
• GC Biopharma corp
• AmerisourceBergen Corporation
• Laboratory Corporation of America Holdings
• Bruker Corporation
• Octapharma AG
• KalVista Pharmaceuticals
• Emergent BioSolutions
• FFF Enterprises, Inc.
• Plasma Technologies, LLC
• LFB SA
• Kamada Ltd.
• PlasmaGen BioSciences Pvt. Ltd.
• Reliance Industries Limited
• Thermo Fisher Scientific, Inc.
• Grifols, SA
• China Biologic Products Holdings, Inc.
• Hemarus Therapeutics Limited
• Access Biologicals LLC
• ADMA Biologics, Inc.
• Baxter International Inc.
• Kedrion SpA

The Plasma Protein Therapeutics Market was valued at USD 32.55 billion in 2023, expected to reach USD 36.19 billion in 2024, and is projected to grow at a CAGR of 11.37%, to USD 69.18 billion by 2030.

Plasma Protein Therapeutics involves treatments derived from human plasma proteins for diseases such as hemophilia, immune deficiencies, and rare disorders. The scope encompasses therapies like immunoglobulins, albumin, and clotting factors designed for critical patient needs. The necessity lies in the unique therapeutic benefits these proteins offer, often essential for patients who lack alternatives. Applications extend from treatment and management of clotting disorders and immune system deficiencies to critical care in emergency medicine. End-use is primarily in hospitals, specialized clinics, and research institutions, where there is a dire need for effective therapies. The market is driven by factors like increasing prevalence of rare diseases, technological advancements in plasma fractionation, and rising healthcare expenditure. Latest opportunities arise from the surge in demand for immunoglobulins and innovations in recombinant therapies, coupled with market expansion in emerging regions due to improving healthcare infrastructure. To capitalize on these opportunities, businesses should focus on strategic partnerships, and regional expansions. However, market growth is currently challenged by constraints such as the high cost of therapies, stringent regulatory frameworks, and the ethical issues surrounding plasma donation. Additionally, complexities in product manufacturing and limited plasma supply pose significant hurdles. The best areas for innovation include developing new plasma-derived therapies, enhancing plasma collection efficiency, and exploring genetic engineering to improve recombinant alternatives. The market is primarily characterized by intense competition, where strategic mergers, acquisitions, and collaborations are common in fostering growth. Businesses should prioritize investment in research for novel therapies and potential synthetic alternatives to boost supply. Overall, the market is poised for growth, driven by innovations and expanding access, but must navigate the challenges of cost, regulation, and supply chain complexities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Plasma Protein Therapeutics Market

The Plasma Protein Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increased Prevalence of Autoimmune and Neurological Diseases
  • Need for Regular Infusions or Injections Throughout the Life of the Patient
  • Surging Access and Affordability of Plasma Protein Therapies for Patients
• Market Restraints
  • Adverse Effects of Plasma Protein Therapeutics
• Market Opportunities
  • Increasing Research and Development Activity Related to the Plasma Protein
  • Development of Efficient Protein Plasma Extraction/Manufacturing Process
• Market Challenges
  • Strict Regulations Pertaining to Handling of Plasma Protein

Porter's Five Forces: A Strategic Tool for Navigating the Plasma Protein Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Plasma Protein Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Plasma Protein Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Plasma Protein Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Plasma Protein Therapeutics Market

A detailed market share analysis in the Plasma Protein Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Plasma Protein Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Plasma Protein Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Plasma Protein Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Bio Products Laboratory Ltd., CSL Limited, Takeda Pharmaceutical Company Limited, DiaPharma, GC Biopharma corp, AmerisourceBergen Corporation, Laboratory Corporation of America Holdings, Bruker Corporation, Octapharma AG, KalVista Pharmaceuticals, Emergent BioSolutions, FFF Enterprises, Inc., Plasma Technologies, LLC, LFB SA, Kamada Ltd., PlasmaGen BioSciences Pvt. Ltd., Reliance Industries Limited, Thermo Fisher Scientific, Inc., Grifols, S.A., China Biologic Products Holdings, Inc., Hemarus Therapeutics Limited, Access Biologicals LLC, ADMA Biologics, Inc., Baxter International Inc., and Kedrion S.p.A..

Market Segmentation & Coverage

This research report categorizes the Plasma Protein Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Albumins, C1-esterase Inhibitors, Coagulation Factors, Hyperimmune Globulins, and Immunoglobulins.
• Based on Application, market is studied across Hereditary Angioedema, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, and Secondary Immunodeficiency.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased Prevalence of Autoimmune and Neurological Diseases
    • 5.1.1.2. Need for Regular Infusions or Injections Throughout the Life of the Patient
    • 5.1.1.3. Surging Access and Affordability of Plasma Protein Therapies for Patients
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse Effects of Plasma Protein Therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing Research and Development Activity Related to the Plasma Protein
    • 5.1.3.2. Development of Efficient Protein Plasma Extraction/Manufacturing Process
  • 5.1.4. Challenges
    • 5.1.4.1. Strict Regulations Pertaining to Handling of Plasma Protein
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising usage of C1-esterase inhibitors to control and prevent the swelling attacks associated with HAE
  • 5.2.2. Application: Growing application of plasma protein therapeutics in the secondary immunodeficiency due to prevalence of cancer and autoimmune diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Plasma Protein Therapeutics Market, by Product

• 6.1. Introduction
• 6.2. Albumins
• 6.3. C1-esterase Inhibitors
• 6.4. Coagulation Factors
• 6.5. Hyperimmune Globulins
• 6.6. Immunoglobulins

7. Plasma Protein Therapeutics Market, by Application

• 7.1. Introduction
• 7.2. Hereditary Angioedema
• 7.3. Idiopathic Thrombocytopenic Purpura
• 7.4. Primary Immunodeficiency Disorder
• 7.5. Secondary Immunodeficiency

8. Americas Plasma Protein Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Plasma Protein Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Plasma Protein Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia
  • 11.3.2. PlasmaGen Biosciences Opens New, State-of-the-Art Manufacturing Facility for Blood Plasma Products in Kolar, Bengaluru
  • 11.3.3. Takeda to build USD 770 million plasma-derived therapy plant in Japan

Companies Mentioned

• 1. Bio Products Laboratory Ltd.
• 2. CSL Limited
• 3. Takeda Pharmaceutical Company Limited
• 4. DiaPharma
• 5. GC Biopharma corp
• 6. AmerisourceBergen Corporation
• 7. Laboratory Corporation of America Holdings
• 8. Bruker Corporation
• 9. Octapharma AG
• 10. KalVista Pharmaceuticals
• 11. Emergent BioSolutions
• 12. FFF Enterprises, Inc.
• 13. Plasma Technologies, LLC
• 14. LFB SA
• 15. Kamada Ltd.
• 16. PlasmaGen BioSciences Pvt. Ltd.
• 17. Reliance Industries Limited
• 18. Thermo Fisher Scientific, Inc.
• 19. Grifols, S.A.
• 20. China Biologic Products Holdings, Inc.
• 21. Hemarus Therapeutics Limited
• 22. Access Biologicals LLC
• 23. ADMA Biologics, Inc.
• 24. Baxter International Inc.
• 25. Kedrion S.p.A.

LIST OF FIGURES

• FIGURE 1. PLASMA PROTEIN THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PLASMA PROTEIN THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PLASMA PROTEIN THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 35. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. INDONESIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. INDONESIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. MALAYSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. MALAYSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. PHILIPPINES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. PHILIPPINES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. SINGAPORE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. SINGAPORE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. TAIWAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. TAIWAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. THAILAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. THAILAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. VIETNAM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. VIETNAM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 62. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. DENMARK PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. EGYPT PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. FINLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. ISRAEL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. NETHERLANDS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. NIGERIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. NORWAY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. POLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. QATAR PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. SAUDI ARABIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. SWEDEN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. SWITZERLAND PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. TURKEY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. UNITED ARAB EMIRATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 105. PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023